glp 1 depression New Evernorth research shows GLP-1 medications - commonly used for type 2 diabetes and obesity New Study: GLP-1s REDUCED Depression

Presented for research literature review only Baudouin-Cornu P et al

J&J will make initial payments of $785 million, including a $465 million equity investment, plus up to $140 million in milestone payments, with Sail contributing its endless RNA (eRNA) and targeted nanoparticle delivery technology

Its primary role involves tissue building and repair

Patients routinely fly in to be evaluated by COEM, as we serve patients internationally

While Eli Lilly and Novo Nordisk benefit from pricing power and the financial resources to push innovation further, they also have the potential to face regulatory scrutiny and patent challenges